Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3 Hours versus 3-4.5 Hours

2018 ◽  
Vol 27 (4) ◽  
pp. 1033-1040 ◽  
Author(s):  
Ichiro Deguchi ◽  
Norio Tanahashi ◽  
Masaki Takao
Keyword(s):  
Clinical Study ◽  
Cerebral Infarction ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Low Dose ◽  
Recombinant Tissue Plasminogen Activator ◽  
Acute Cerebral Infarction ◽  
Tissue Plasminogen

Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction

2020 ◽  
Vol 20 (12) ◽  
pp. 7781-7786
Author(s):  
Tao Wu ◽  
Peiling Li ◽  
Deke Sun
Keyword(s):  
Cerebral Infarction ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Clinical Efficacy ◽  
Intracranial Hemorrhage ◽  
Recombinant Tissue Plasminogen Activator ◽  
Acute Cerebral Infarction ◽  
Clinical Effects ◽  
Nihss Score ◽  
Tissue Plasminogen

To assess the efficacy of intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis on clinical outcomes and risk of death in patients with acute cerebral infarction. Patients (n = 258) with acute cerebral infarction, treated within 4–5 h of the episode, were grouped according to whether intravenous thrombolysis was performed using rt-PA or not. Both groups received routine treatment for cerebral infarction, but the former received rt-PA intravenously at a dosage of 0.9 mg/kg. The National Institutes of Health Stroke Scale (NIHSS) score, clinical efficacy, and risk of bleeding and death were compared between the two groups. The NIHSS score and clinical effects for the rt-PA group were more favorable than those of its counterpart (P < 0.05), though there was no significant difference in risk of an intracranial hemorrhage. The mortality rate for the rt-PA group was lower than that of the control group (P < 0.05). Administration of intravenous rt-PA thrombolysis within 4.5 h of an acute cerebral infarction had a significant impact and did not increase risk of intracranial hemorrhage or death.

scholarly journals Coronary aspiration thrombectomy after using intravenous recombinant tissue plasminogen activator in a patient with acute ischemic stroke: a case report

2019 ◽  
Vol 47 (9) ◽  
pp. 4551-4556 ◽  
Author(s):  
Ton Mai Duy ◽  
Phuong DaoViet ◽  
Dung Nguyen Tien ◽  
Quang-Anh Nguyen ◽  
Thien Nguyen Tat ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Tissue Plasminogen Activator ◽  
Low Dose ◽  
Recombinant Tissue Plasminogen Activator ◽  
Aspiration Thrombectomy ◽  
Tissue Plasminogen ◽  
New Strategy

The complication of myocardial infarction after using intravenous recombinant tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke is rare. Several of these cases have been reported in the first 3 hours after infusion of rt-PA. There is controversy on how to manage treatment of the coronary artery, such as intravenous anticoagulants and antiplatelets, at the same time. We introduce a new strategy for treatment of a patient who had ischemic stroke and developed myocardial infarction after intravenous rt-PA therapy. Our case had coronary and cerebral intervention in combination with low-dose intravenous rt-PA. He was successfully treated for coronary occlusion with aspiration thrombectomy.

Sign in / Sign up

Export Citation Format

Share Document